| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Stereotaxis, Inc.$1.7
-0.04 (-2.3%)
D 35Pipeline Score MedTech · Commercial
Market Cap
187.65 M
EPS
-0.24
P/E Ratio
-
Value Trade
1.15 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
6.29 M
R&D Expenses
2.40 M
Operating CF
-3.44 M
Total Assets
54.03 M
Total Liabilities
34.43 M
Equity
14.36 M
D/E Ratio
12,345
0 %
Week
-1.03 %
1 Month
-7.25 %
3 Month
-14.29 %
6 Month
-72.57 %
5 Year
-97.6 %
All Time
Cash Data
Cash Position
14.62 M
Monthly Burn
1.15 M
Runway
10.7 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
567.80 K
52 Week Range
1.70 - 3.59
% held by Insiders
17.7 %
% held by Institutions
44.82 %
Enterprise Value
183.56 M
Total Shares
97.41 M
Short %
6.32 %
Float Shares
67.50 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $217M
Pipeline ValueValuation Signal
1
Drugs Scored1.2x
rNPV / MCap Top 46%
Micro Cap (rank 493 of 912)
Percentile RankStereotaxis, Inc. faces pipeline headwinds (35/100), with $2.0B risk-adjusted pipeline value, led by Vdrive Lasso navigation, Manual Lasso navigation in Atrial Fibrillation (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vdrive Lasso navigation, Manual Lasso navigation Unknown | Atrial Fibrillation | Phase 3 | NCT01656772 | 46% | $2.0B | COMPLETED | 120 | - | - | Dec 1, 2013 | - | Jul 1, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Stereotaxis remote magnetic navigation platform | atrial fibrillation | — | 2015-01-13 | acute success rate: 100%; general anesthesia free from arrhythmias: 86.6%; local anesthesia free from arrhythmias: 88.8% Read More | Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures Read More | |
Stereotaxis remote magnetic navigation platform | atrial fibrillation | — | 2015-01-13 | acute success rate: 100%; general anesthesia free from arrhythmias: 86.6%; local anesthesia free from arrhythmias: 88.8% Read More | Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures Read More | |
Stereotaxis remote magnetic navigation platform | atrial fibrillation | — | 2015-01-13 | acute success rate: 100%; general anesthesia free from arrhythmias: 86.6%; local anesthesia free from arrhythmias: 88.8% Read More | Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STXS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STXS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STXS▼ -2.3%today
Stereotaxis Completes Acquisition of Robocath
Stereotaxis has completed its acquisition of Robocath, enhancing its capabilities in surgical robotics for endovascular interventions. The integration aims to combine their technologies to innovate robotic solutions for electrophysiology and interventional cardiology. Leaders from both companies express optimism about the strategic benefits and expanded market opportunities resulting from this merger.
Read more →STXSStereotaxis Reports 2026 First Quarter Financial Results & Business Updates
Stereotaxis reported its first quarter financial results for 2026, revealing a revenue decline to $6.3 million. The company achieved important FDA approvals and is optimistic about future growth, anticipating over $40 million in annual revenue. Despite challenges from transitioning away from Johnson & Johnson catheters, initial market adoption of new products is promising.
Read more →STXSStereotaxis Announces First MAGiC Procedures in the United States
Stereotaxis has announced the successful first use of its MAGiC catheter in the United States, which recently received FDA PMA approval. This innovative technology is designed for minimally invasive cardiac ablation procedures, particularly in patients with complex congenital heart disease. The first procedure was performed by Dr. Nathan McConkey, demonstrating the catheter's effectiveness in treating challenging anatomical conditions. The MAGiC catheter enhances precision and safety in cardiac interventions and is expected to considerably improve patient care.
Read more →STXSStereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
Stereotaxis, a leader in surgical robotics for minimally invasive interventions, will report its financial results for the first quarter of 2026 on May 12, 2026. A conference call will be held at 4:30 p.m. EST that day to discuss these results and other corporate developments. The company's innovative technology has been instrumental in providing care for over 150,000 patients worldwide.
Read more →STXSStereotaxis Announces Definitive Agreement to Acquire Robocath
Stereotaxis (NYSE: STXS) has announced a definitive agreement to acquire Robocath, enhancing its capabilities in robotic solutions for endovascular procedures. This acquisition is aimed at integrating complementary technologies, facilitating the growth of advanced robotic platforms in interventional cardiology and neurointerventions. The deal, valued at $20 million upfront plus additional contingent payments, is expected to close in mid-2026 and to provide approximately $2 million in annual revenue in its first year. This strategic move is anticipated to position Stereotaxis favorably in large interventional markets with significant revenue potential.
Read more →STXSStereotaxis Announces FDA Clearance and Launch of Synchrony System
Stereotaxis has announced the FDA clearance for its Synchrony system, designed to modernize interventional cath labs. This system features a 55-inch 4K ultra-high-definition display and offers benefits such as enhanced workflow, remote connectivity, and improved visualization for procedures. The company anticipates over $3 million in revenue from Synchrony systems, and emphasizes its foundational role in future innovations, including AI integration for enhanced clinical insights. The system aims to improve both patient care and operational efficiency in electrophysiology labs.
Read more →STXSStereotaxis Reports 2025 Full Year Financial Results St. Louis, MO
Stereotaxis, a leader in surgical robotics, reported a substantial 20% revenue growth for 2025, signaling positive advancements in their product pipeline. The company obtained regulatory approvals for its key innovations, namely the GenesisX robot and MAGiC ablation catheter. Despite modest early commercial contributions from these new products, Stereotaxis aims to achieve key milestones in 2026, including ramping up production and expanding market access. Their financial outlook remains optimistic with expectations of surpassing $40 million in annual revenue.
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
Stereotaxis (NYSE: STXS) announced it will release its financial results for the fourth quarter and full year of 2025 on March 9, 2026. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results and corporate developments. Stereotaxis is recognized for its innovative surgical robotics in minimally invasive procedures.
Read more →STXSKlinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
Stereotaxis has launched a robotic electrophysiology program at Klinikum Fürth, marking the first of its kind in Germany. The Genesis Robotic Magnetic Navigation System will enhance treatment precision for patients with arrhythmias. Initial treatments have been successful, and the program aims to improve access to advanced cardiac care in the region.
Read more →STXS▲ +8.1%on this news
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
Stereotaxis has received FDA approval for its MAGiC Magnetic Interventional Ablation Catheter, representing a significant advancement in robotic cardiac ablation technology. This catheter aims to enhance treatment options for patients with complex heart rhythm disorders, particularly those who are underserved. With its robotically-navigated design, the catheter offers improved maneuverability and precision compared to traditional methods. Healthcare professionals express optimism regarding the positive implications of this innovation for better patient outcomes in electrophysiology.
Read more →STXSStereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
Stereotaxis, a leader in surgical robotics, will participate in the Piper Sandler 37th Annual Healthcare Conference. CEO David Fischel is set to engage in a fireside discussion and hold one-on-one meetings on December 3rd, 2025. The company is currently experiencing significant regulatory progress and early commercial success.
Read more →STXS▼ -14.7%on this news· ran to -26% by day 3
Stereotaxis Reports 2025 Third Quarter Financial Results
Stereotaxis reported its third quarter financial results for 2025, highlighting a revenue of $7.5 million, driven by the launch of new robotic systems and a strong performance from recurring revenue. The company experienced an increase in operating loss but expects revenue growth to exceed $9 million in Q4. Regulatory advancements and product launches are expected to bolster future performance.
Read more →STXSGenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
Stereotaxis has received FDA 510(k) clearance for its GenesisX Robotic Magnetic Navigation System, which improves the accessibility of robotic technology in endovascular surgery. The system's compact design allows for easy installation in existing cath labs without major modifications. This marks a significant step in advancing robotic adoption in surgical procedures.
Read more →STXSStereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
Stereotaxis, a leader in surgical robotics, announced it will report its third quarter financial results for 2025 on November 11, 2025. The financial results will be discussed during a conference call at 4:30 p.m. ET. Stereotaxis has gained recognition for its innovative solutions in minimally invasive endovascular procedures. This event highlights the company's ongoing commitment to improving patient care through advanced robotic technology.
Read more →STXSStereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs
Stereotaxis has announced the launch of its Synchrony system in Europe after obtaining CE Mark and has submitted a 510(k) application to the FDA. The system aims to modernize interventional cath labs with advanced features like a 55” 4K display and cloud-based connectivity. Experts highlight its potential to enhance workflows and improve patient care through innovative technology.
Read more →STXSStereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
Stereotaxis and CardioFocus have entered a collaboration to advance robotic Pulsed Field Ablation (PFA) technology for treating cardiac arrhythmias. The partnership combines their proprietary technologies to create the first robotic PFA solution, building on successful preclinical studies. Both companies aim to transition to clinical trials and enhance patient care in electrophysiology.
Read more →STXSErasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System
Stereotaxis announced that Erasmus Medical Center successfully performed the first procedures using the Genesis Robotic Magnetic Navigation System. This system aims to improve cardiovascular care, particularly for arrhythmia patients. The collaboration highlights the importance of robotic technology in enhancing patient outcomes and safety during minimally invasive procedures.
Read more →STXS▼ -5.9%on this news
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
Stereotaxis has successfully completed the first procedures using the MAGiC Sweep catheter, a robotic high-density electrophysiology mapping tool. Conducted by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center, the procedures demonstrated the catheter's effectiveness in mapping complex cardiac anatomy. Following FDA clearance, Stereotaxis has begun its commercial launch in the U.S. and is seeking regulatory approval in Europe.
Read more →STXS▼ -5.9%on this newsshared move
Stereotaxis to Present at Upcoming Investor Conferences
Stereotaxis (NYSE: STXS) announced that CEO David Fischel will present at two investor conferences in New York City this September. The company aims to highlight its technological advancements and growth strategy. Additionally, one-on-one meetings with Fischel can be arranged for interested investors. Stereotaxis is known for its innovative surgical robotics in minimally invasive procedures.
Read more →STXSStereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025
Stereotaxis will present its surgical robotics technology at the HRX 2025 conference in Atlanta, Georgia, from September 4-6. CEO David Fischel will engage in a roundtable discussion, and a panel of experts will explore advanced ablation techniques. The event emphasizes the integration of robotics and digital technologies in cardiovascular medicine.
Read more →STXSStereotaxis Reports 2025 Second Quarter Financial Results St. Louis, MO
Stereotaxis (NYSE: STXS) announced its financial results for the second quarter of 2025, showcasing a remarkable 95% revenue increase year-over-year, attributed to new product innovations and regulatory successes. The company highlighted the FDA clearance of the MAGiC Sweep, its first interventional catheter clearance in almost two decades, as a pivotal factor in revenue growth. Despite improvements, Stereotaxis reported an operating loss of $4.0 million and negative cash flow of $3.7 million, yet maintains an optimistic outlook for double-digit revenue growth for the full year. The financing deal in July bolstered its cash reserves to $18.8 million, enabling continued advancement in their product ecosystem.
Read more →STXS▲ +15.1%on this news
Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter
Stereotaxis has achieved FDA 510(k) clearance for its MAGiC Sweep catheter, marking a significant development in electrophysiology. This catheter is touted as the world's first robotically navigated high-density mapping catheter, designed to enhance the diagnosis and treatment of complex arrhythmias. With its unique features, including a high density of electrodes and an atraumatic design, MAGiC Sweep aims to facilitate more accurate and efficient cardiac procedures. This clearance signifies Stereotaxis' commitment to innovating in the field of robotic surgery.
Read more →STXSStereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
Stereotaxis (NYSE: STXS) has announced it will report its financial results for the second quarter of 2025 on August 7, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and any corporate developments. The company's advancements in surgical robotics aim to enhance patient care and operational efficiency in interventional laboratories globally. This call presents an opportunity for investors and stakeholders to gain insight into the company's performance and future direction.
Read more →STXSStereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock Led by Strategic Industry Partner and Select Institutional Investors Proceeds Strengthen Balance Sheet and Support Commercialization of Innov
Stereotaxis, Inc. announced a $12.5 million registered direct offering of common stock, led by a strategic industry partner and select institutional investors. The proceeds will be utilized to accelerate product commercialization and support research and development. The initial closing of approximately $8.5 million is expected on July 18, 2025, while a second closing of $4 million is planned for on or before November 25, 2025. The offering is being executed under a prospectus supplement to an existing shelf registration statement.
Read more →STXSStereotaxis Reports 2025 First Quarter Financial Results St. Louis, MO
Stereotaxis reported its financial results for the first quarter of 2025, highlighting a 9% increase in total revenue to $7.5 million. Key achievements included a 29% growth in recurring revenue and successful demonstrations of the GenesisX robotic system at global conferences. Despite these positives, the company faced an increased net loss of $5.8 million and rising operating expenses. Looking ahead, Stereotaxis anticipates double-digit revenue growth for the full year, fueled by potential market expansion and innovative product launches.
Read more →STXS▲ +9.3%on this news
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
Stereotaxis, a leader in surgical robotics for minimally invasive interventions, will release its financial results for the first quarter of 2025 on May 12, 2025, after the U.S. markets close. The company plans to host a conference call and webcast that same day to discuss the results and other corporate developments. This communication highlights the company's commitment to transparency and involvement with its stakeholders.
Read more →STXSStereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
Stereotaxis, a leader in surgical robotics, will host the first live demonstration of its GenesisX Robotic System at the Heart Rhythm Symposium (HRS) in San Diego from April 24-27, 2025. This system enhances accessibility and efficiency for healthcare providers with its compact design and ease of installation. GenesisX has previously obtained CE Mark approval in Europe and is currently under FDA review. The presentation aims to engage the electrophysiology community and showcase Stereotaxis's portfolio of technologies.
Read more →STXS▲ +15.1%on this news
Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
Stereotaxis (NYSE: STXS) has been recognized by NVIDIA at the GTC conference for its innovative surgical robotic technology, marking a significant endorsement in the medical field. Additionally, the company has been accepted into the NVIDIA Connect program, which offers support with software and development resources. Stereotaxis's robotic systems are actively used in various hospitals worldwide, aiming to further enhance medical interventions with artificial intelligence and automation. The company plans to invest in expanding its capabilities to improve patient care and operational efficiency in the healthcare space.
Read more →STXS▼ -5.3%on this news
Stereotaxis to Present at 37th Annual Roth Conference
Stereotaxis (NYSE: STXS) announced that its Chairman and CEO, David Fischel, will present at the 37th Annual Roth Conference in Dana Point, California. Mr. Fischel will also be available for individual meetings on March 17th, 2025. During the conference, the company aims to showcase its innovative technology and growth strategy to the investment community. Stereotaxis is noted for its advancements in minimally invasive endovascular surgical robotics, having treated over 150,000 patients globally.
Read more →STXS▼ -5.8%on this news
Stereotaxis Reports 2024 Full Year Financial Results St. Louis, MO
Stereotaxis reported its financial results for the fourth quarter and full year 2024, showing a 39% increase in revenue year-over-year. The company achieved regulatory milestones, including approvals for multiple products in Europe and China, contributing to their strategic transformation. Despite a positive cash flow in the fourth quarter, Stereotaxis recorded an increased net loss compared to the previous year. Looking ahead, the company anticipates continued revenue growth and improvements in recurring revenue through 2025.
Read more →STXS▼ -5.8%on this news
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
Stereotaxis has announced the regulatory submission of its EMAGIN 5F catheter, the first robotically navigated device intended for expanding the use of Robotic Magnetic Navigation in endovascular surgeries. This innovative catheter is designed to enhance navigation in complex vascular anatomy, facilitating minimally invasive procedures for conditions such as stroke and cancer. Both FDA and European CE Mark clearances are anticipated, with a market launch planned for the second half of the year. The company aims to leverage this technology to develop a comprehensive portfolio of robotic endovascular devices.
Read more →STXS▼ -5.8%on this news
Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance
Stereotaxis has submitted a 510(k) application to the FDA for its MAGiC Sweep catheter, marking the first robotically navigated high-density EP mapping device. This innovative catheter aims to enhance cardiac ablation procedures by providing rapid and detailed electroanatomical mapping while ensuring safety through its atraumatic design. Following expected regulatory approvals, Stereotaxis plans to launch MAGiC Sweep commercially in the latter half of the year, supporting its strategic transformation in robotic interventions.
Read more →STXSStereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
Stereotaxis, a leader in surgical robotics for minimally invasive procedures, announced its participation in the TD Cowen Healthcare Conference on March 3, 2025. CEO David Fischel will present the company’s overview and strategy during the event. This participation indicates the company's ongoing commitment to share updates on its advancements in robotic surgical technology.
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Stereotaxis (NYSE: STXS) has announced its plans to release financial results for the fourth quarter and full year of 2024 on March 3, 2025. The company will conduct a conference call at 8:30 a.m. ET to discuss the results and corporate developments. Stereotaxis is recognized for its innovative surgical robotics used in minimally invasive procedures and has treated over 150,000 patients globally.
Read more →STXS▲ +5.3%on this newsshared move
Stereotaxis Announces First GenesisX Robotic System Order
Stereotaxis has announced its first order for the GenesisX robotic system, marking a significant step towards its commercial launch. The system aims to enhance the accessibility of Robotic Magnetic Navigation in endovascular surgery, featuring a compact design and efficient functionality. With CE Mark approval already obtained in Europe, Stereotaxis is now focused on gaining FDA clearance and preparing for market introduction. The company has outlined plans to enhance compatibility with existing systems and demonstrate real-world usage in clinical settings.
Read more →STXS▲ +5.5%on this newsshared move
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
Stereotaxis has announced that it received European CE Mark approval for its MAGiC ablation catheter, a significant achievement in the field of surgical robotics for cardiac procedures. This catheter, designed to treat heart arrhythmias, builds on nearly two decades of innovation and prior robotic procedures. The approval is expected to facilitate enhanced adoption of this technology among physicians across Europe, highlighting the advancements made in treatment precision and patient safety.
Read more →STXSStereotaxis’ GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Stereotaxis announced that its GenesisX robotic system will be showcased for the first time at the RSNA 2024 Annual Meeting in Chicago, Illinois. This event highlights the collaboration with Neusoft Medical Systems, a leader in advanced medical imaging solutions. The GenesisX system aims to improve precision, efficiency, and safety in endovascular procedures. According to both CEOs, this partnership is expected to deliver groundbreaking technologies to enhance patient care globally.
Read more →STXSStereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
Stereotaxis (NYSE: STXS) announced that its CEO, David Fischel, will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024. The presentation will focus on the company's technology and growth strategy, with Fischel available for one-on-one meetings afterward. The company highlighted its progress in robotic surgical innovations and its aim to enhance patient care and operating room efficiency. Stereotaxis has treated over 150,000 patients worldwide, reflecting its significant impact in the field.
Read more →STXS▲ +10.2%on this newsshared move
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Stereotaxis, in collaboration with Shanghai MicroPort EP Medtech Co., Ltd., has received regulatory approval from China's National Medical Products Administration for the Genesis RMN System. This approval marks a significant milestone, allowing the introduction of advanced robotic technology in China’s electrophysiology community. MicroPort EP is set to launch the Genesis system commercially, enhancing Stereotaxis' presence in the region. The robot is already established in the US and Europe, where it has been instrumental in treating thousands of patients.
Read more →STXSStereotaxis Reports 2024 Third Quarter Financial Results St. Louis
Stereotaxis reported solid financial results for the third quarter of 2024, highlighting an 18% increase in revenues compared to the same quarter last year. The growth was supported by strong demand for their Genesis systems and successful integration of the recently acquired APT. The company is also anticipating future regulatory approvals that could enhance their product offerings. However, they reported an increased operating loss and a negative cash flow, indicating ongoing challenges in financial management.
Read more →STXSStereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024
Stereotaxis (NYSE: STXS) announced it will release its financial results for the third quarter of 2024 on November 11, 2024, after the U.S. market closes. A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the results and any corporate developments. The company is recognized for its innovations in surgical robotics, aiming to enhance patient care and improve operating room efficiency.
Read more →STXSStereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
Stereotaxis (NYSE: STXS) will participate in the Society for Cardiac Robotic Navigation's Annual Meeting on October 28-29 in Lisbon, Portugal. This event is focused on robotic technologies in cardiology, featuring over forty expert physicians discussing various advancements and clinical applications. Stereotaxis will highlight its robotic technologies through presentations and demonstrations, emphasizing their significance in minimally invasive endovascular interventions. The conference will cover topics like AI developments in the operating room and innovations in robotic catheter systems.
Read more →STXSStereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress
Stereotaxis (NYSE: STXS) announced its robotic technology will be featured at the HRX digital health conference from September 5-7, 2024, in Atlanta, Georgia. The conference, organized by the Heart Rhythm Society, focuses on advancing digital technologies in cardiovascular medicine. CEO David Fischel will participate in discussions centered around the future of electrophysiology labs and the role of robotics in caring for heart rhythm patients. This involvement emphasizes Stereotaxis's commitment to innovating patient care and improving health outcomes through surgical robotics.
Read more →STXSStereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
Stereotaxis has announced the achievement of a CE mark for its next generation robotic system, GenesisX, which has also been submitted for 510(k) clearance to the FDA in the United States. The GenesisX system aims to improve accessibility to robotic technology for minimally-invasive endovascular surgery, easing the installation burdens traditionally associated with such systems. This innovation incorporates built-in magnetic shielding and operates on standard electrical power, making it more hospitable for hospitals to adopt. Stereotaxis is gearing up for a significant launch of GenesisX in 2025, pending necessary regulatory approvals.
Read more →STXSStereotaxis Reports 2024 Second Quarter Financial Results
Stereotaxis reported its second quarter financial results for 2024, which revealed a total revenue of $4.5 million, down from $7.9 million in the previous year. Despite achieving key milestones including obtaining a CE mark for GenesisX and closing the acquisition of Access Point Technologies, the company faced challenges with revenue recognition due to delays in hospital construction schedules. Stereotaxis anticipates improved revenue and cash flow in the latter half of 2024 and aims to maintain its financial strength without the need for additional financing. The operating and net losses rose compared to the previous year, highlighting ongoing financial challenges.
Read more →STXSStereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024
Stereotaxis, a leader in surgical robotics, has announced that it will release its financial results for the second quarter of 2024 on August 12, 2024. The company plans to hold a conference call and webcast at 4:30 p.m. EST to discuss these results and any corporate developments. Stereotaxis continues to advance its mission of enhancing patient care with its innovative robotic systems and instruments.
Read more →STXSStereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir St. Louis
Stereotaxis has announced the appointment of Nachum "Homi" Shamir to its Board of Directors, enhancing its leadership capabilities. Shamir brings extensive experience from his roles at Luminex Corporation and Given Imaging, which may aid Stereotaxis in executing its growth strategies. Both Shamir and Chairman David Fischel have expressed confidence in the company's future potential as it seeks to refine its strategy and expand its commercial capabilities in robotic surgery. This appointment comes at a critical time as Stereotaxis aims to transform endovascular surgical practices.
Read more →STXSStereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
Stereotaxis has announced the receipt of CE Mark recertification under the European Union's new Medical Device Regulation (MDR) framework, validating its compliance with stringent standards for quality and safety. This recertification covers all current Stereotaxis devices available in Europe and supports future regulatory clearances for novel innovations. The achievement marks a significant milestone for the company's operations in the surgical robotics sector.
Read more →STXSStereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
Stereotaxis has been invited to present its innovative robotic solution at the HRS Africa Summit 2024, highlighting a plan to utilize telerobotic technology for cardiac ablation therapy in underserved African regions. The proposed mobile robotic electrophysiology lab aims to connect expert physicians with patients lacking access to this crucial treatment. This initiative could improve healthcare access and quality in Africa, where the infrastructure for electrophysiology is almost nonexistent. The technology and logistics have been validated, indicating a feasible path for implementation.
Read more →STXSStereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
Stereotaxis has announced a definitive agreement to acquire Access Point Technologies (APT), enhancing its portfolio in surgical robotics for endovascular procedures. The acquisition aims to advance the treatment of complex arrhythmias and leverage innovative catheter technology developed by APT. Expected to close in the third quarter, the transaction involves an upfront payment and contingent payments tied to key milestones, with APT projected to contribute approximately $5 million in annual revenue within the first year post-acquisition. This strategic move is positioned to strengthen Stereotaxis's market presence in electrophysiology.
Read more →STXSStereotaxis Reports 2024 First Quarter Financial Results
Stereotaxis (NYSE: STXS) announced its financial results for the first quarter of 2024, revealing a revenue growth of 5% year-over-year, totaling $6.9 million. The company noted a positive trajectory in its system backlog and growth from its recent orders for Genesis systems. Significant advancements were made in regulatory submissions and product testing, with expectations for further growth across new initiatives. However, Stereotaxis continues to report a net loss of ($4.5) million and negative cash flow for the quarter.
Read more →STXSStereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
Stereotaxis, a leader in surgical robotics, will report its financial results for the first quarter of 2024 on May 13, 2024. The company plans to host a conference call and webcast that same day to discuss these results and related corporate developments. This announcement highlights Stereotaxis's commitment to keeping investors informed about its performance and innovations in minimally invasive endovascular intervention.
Read more →STXSStereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
Stereotaxis has announced regulatory submissions for its MAGiC catheter in Europe and the United States, following promising initial clinical results. The MAGiC catheter, a robotically navigated magnetic ablation device, aims to improve patient safety and effectiveness in cardiac procedures. The device has shown 100% acute efficacy in the first human trials with no adverse events reported. Stereotaxis anticipates commercial availability of the MAGiC catheter pending regulatory approvals.
Read more →STXSStereotaxis Reports 2023 Full Year Financial Results
Stereotaxis (NYSE: STXS) has reported its financial results for the fourth quarter and full year 2023, highlighting challenges due to production shortages and royalty losses. Despite these setbacks, the company is optimistic about upcoming product launches and regulatory approvals for its robotic systems. CEO David Fischel noted the foundation for future growth has been established and expects significant recovery in revenue and market position in the coming year. The company ended 2023 with a solid backlog and a focus on advancing its transformative product ecosystem.
Read more →STXS▲ +8.9%on this news
Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Stereotaxis, a leader in surgical robotics, is set to release its financial results for the fourth quarter and full year of 2023 on March 4, 2024. The release will be followed by a conference call and webcast to discuss the results and corporate developments. The company continues to focus on innovative solutions for minimally invasive endovascular interventions, with a strong track record in patient care and technology deployment across multiple regions.
Read more →STXSStereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
Stereotaxis announced the successful treatment of the first patients using its MAGiC Ablation Catheter, a robotically navigated device designed for minimally invasive cardiac procedures. These treatments were carried out by medical professionals at Vilnius University Hospital Santaros Klinikos in Lithuania, marking the beginning of a clinical trial aimed at supporting CE Mark submission. The catheter's promising performance has generated optimism within the electrophysiology community regarding advancements in robotic catheter technology.
Read more →STXSStereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference
Stereotaxis, a leader in surgical robotics, will participate in the Piper Sandler 35th Annual Healthcare Conference. During the event, CEO David Fischel will present on the company's business and technology in a Fireside Discussion. This event will take place on November 30, 2023, and Fischel is also available for one-on-one meetings with investors. Stereotaxis aims to highlight its innovative technology and growth strategy, emphasizing its commitment to providing advanced patient care.
Read more →STXS▼ -10.7%on this news
Stereotaxis Reports 2023 Third Quarter Financial Results
Stereotaxis (NYSE: STXS) reported its third quarter financial results for 2023, showcasing revenue growth driven by strong demand for its Genesis robot systems. The company has a solid system backlog of $13 million and anticipates continued growth after expected approvals for the MAGiC ablation catheter. Despite the positive aspects, the firm also experienced an increase in net loss compared to the same period last year. Overall, while Stereotaxis is advancing its innovative product strategy, it faces challenges with recurring revenue declines.
Read more →STXSStereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023
Stereotaxis, a leader in surgical robotics for minimally invasive procedures, will announce its third quarter 2023 financial results on November 9, 2023. A conference call will be held at 10 a.m. EST to discuss these results and related corporate developments. The company aims to improve patient care with their innovative robotics technology, having treated over 100,000 patients globally.
Read more →STXSStereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation
Stereotaxis (NYSE: STXS) will participate in the 7th Annual Meeting of the Society for Cardiac Robotic Navigation on October 19-20 in Washington, DC. The meeting aims to foster collaboration among healthcare professionals using robotic technologies in cardiology. Key topics will include advancements in artificial intelligence, robotic applications for complex arrhythmias, and long-distance telerobotic collaboration. The conference will feature over thirty leading physicians from various global regions, further highlighting the growing momentum of robotics in the medical field.
Read more →STXS▲ +13.4%on this news
Stereotaxis Reports 2023 Second Quarter Financial Results
Stereotaxis (NYSE: STXS) reported its second quarter financial results for 2023, highlighting a 28% revenue growth driven by increasing demand for its robotic technology. The company has secured orders for two Genesis systems and is experiencing a robust system backlog. A strategic collaboration with Abbott was announced, which is expected to enhance adoption of their integrated technology. However, there are concerns about recurring revenue, which was impacted by missing catheter royalties from the previous year, while losses have not significantly changed compared to the previous year.
Read more →STXSStereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients
Stereotaxis has successfully initiated the first integrated procedures utilizing Abbott’s EnSite X EP System alongside its own Robotic Magnetic Navigation System. Conducted by renowned physicians in the Netherlands and Germany, these procedures combine advanced cardiac mapping with robotic technology. This integration aims to enhance treatment efficiency for patients suffering from arrhythmias. Stereotaxis continues to lead in pioneering surgical robotics aimed at improving minimally invasive interventions.
Read more →STXSStereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023
Stereotaxis, a leader in surgical robotics for minimally invasive procedures, will announce its second-quarter financial results on August 10, 2023. A conference call is scheduled for the same day at 10 a.m. EST, where corporate developments will also be discussed. This provides an opportunity for investors and stakeholders to gain insights into the company's performance and future direction. Stereotaxis has been recognized for its innovative technologies and their impact on patient care across various regions.
Read more →STXSStereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter St. Louis
Stereotaxis (NYSE: STXS) announced its intention to initiate a first-in-human trial to support the CE Mark application for its MAGiC catheter, a device designed for minimally invasive cardiac ablation procedures. The company made a prior CE Mark submission in July 2022, but has received a request from the European Notified Body for additional clinical data due to evolving interpretations of EU Medical Device Regulation. Despite these regulatory challenges, Stereotaxis remains optimistic about its innovation strategy and expects continued revenue growth for 2023.
Read more →STXSStereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
Stereotaxis (NYSE: STXS) has announced that its CEO, David Fischel, will participate in the 20th Annual Craig-Hallum Institutional Investor Conference, scheduled for May 31, 2023. During the conference, Fischel will engage in one-on-one meetings with attendees to discuss the company's innovative technology and growth strategy. Stereotaxis is known for its advancements in surgical robotics for minimally invasive endovascular procedures, having treated over 100,000 patients globally.
Read more →STXS▲ +33.1%on this news
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
Stereotaxis has partnered with Abbott to combine their mapping and robotic technologies, aiming to enhance treatment for patients with abnormal heart rhythms. The collaboration has led to successful integration of Abbott’s EnSite X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. This advancement streamlines procedural workflows for physicians and provides improved diagnostic and therapeutic capabilities. The integrated solutions are already cleared for use in Europe, with additional regulatory approvals anticipated soon.
Read more →STXSStereotaxis Reports 2023 First Quarter Financial Results
Stereotaxis (NYSE: STXS) has released its financial results for the first quarter of 2023, reporting revenue of $6.5 million, a decline from $7.0 million in the same period last year. The company remains optimistic about achieving double-digit revenue growth thanks to an expanding order pipeline and successful regulatory processes. However, Stereotaxis also reported an increased net loss of $5.6 million, reflecting higher operating expenses driven by research and development. Despite these challenges, management expressed confidence in upcoming product launches and market strategies.
Read more →STXSStereotaxis to Report First Quarter 2023 Financial Results on May 9, 2023
Stereotaxis (NYSE: STXS) has announced that it will release its financial results for the first quarter of 2023 on May 9, 2023, before U.S. markets open. A conference call and webcast will take place at 10 a.m. EST that day to discuss the results and other corporate developments. Stereotaxis is recognized for its pioneering role in surgical robotics aimed at enhancing minimally invasive endovascular interventions.
Read more →STXS▼ -6.2%on this news
Stereotaxis Reports 2022 Full Year Financial Results
Stereotaxis reported its full-year financial results for 2022, highlighting a revenue drop to $28.1 million from $35.0 million in 2021 due to delays in system placements. However, the company anticipates double-digit revenue growth in 2023, supported by a strong order backlog of $14.8 million and new product launches. The CEO emphasized the importance of a strategic transition toward a comprehensive product ecosystem, which aims to tackle existing market limitations and facilitate substantial growth. Despite challenges in 2022, the outlook appears optimistic with a focus on upcoming innovations and sustained order growth.
Read more →STXSStereotaxis to Present at Cowen 43rd Annual Health Care Conference
Stereotaxis (NYSE: STXS) announced its participation in the Cowen 43rd Annual Health Care Conference, where CEO David Fischel will discuss the company's business and technology. The event is scheduled for March 6, 2023, with Fischel available for one-on-one meetings throughout the day. Stereotaxis emphasizes its leadership in surgical robotics aimed at minimally invasive procedures, highlighting its mission to enhance patient care and operational efficiency in the medical field.
Read more →STXS▲ +7%on this news
Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
Stereotaxis has announced that it will report its financial results for the fourth quarter and full year of 2022 on March 3, 2023, prior to the market opening. A conference call and webcast will be conducted at 10 a.m. EST to discuss the results and any significant corporate developments. The company specializes in surgical robotics for minimally invasive endovascular interventions, revealing their commitment to advancing healthcare technology.
Read more →STXSStereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference
ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Health
Read more →STXSStereotaxis Reports 2022 Third Quarter Financial Results
Reports 2022 Third Quarter Financial Results LOUIS, MO, Nov. 10, 2022 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended Sep
Read more →STXSStereotaxis to Report Third Quarter Financial Results on November 10, 2022
ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 20
Read more →STXSStereotaxis Receives St. Louis Mayor’s Innovation Award for 2022
ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O
Read more →STXS▼ -18.7%on this news
Stereotaxis Reports 2022 Second Quarter Financial Results
Reports 2022 Second Quarter Financial Results LOUIS, MO, Aug. 9, 2022 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended Ju
Read more →STXSStereotaxis to Report Second Quarter Financial Results on August 9, 2022
ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022
Read more →STXSStereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter
ST. LOUIS, July 11, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark submission for its MAGiC™ catheter. The MAGiC catheter is a robotically navigated
Read more →STXSStereotaxis Reports 2022 First Quarter Financial Results
Reports 2022 First Quarter Financial Results LOUIS, May 10, 2022 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31
Read more →STXSStereotaxis to Report First Quarter Financial Results on May 10, 2022
ST. LOUIS, April 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 first quarter on Tuesday, May 10, 2022 be
Read more →STXSStereotaxis Announces Grand Opening of New Global Headquarters in St. Louis
ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global headquarters facility in downtown St
Read more →STXS▼ -26.5%on this news
Stereotaxis Reports 2021 Full Year Financial Results
Reports 2021 Full Year Financial Results LOUIS, Mar. 3, 2022 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year end
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2021 fourth quarter and full year ended Decembe
Read more →STXS▲ +9.6%on this news
Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication
ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using R
Read more →STXSStereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics
ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will includ
Read more →STXS▲ +21.2%on this news
Stereotaxis Reports 2021 Third Quarter Financial Results
Reports 2021 Third Quarter Financial Results LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 3
Read more →STXSStereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Meeting
ST. LOUIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announces it will attend the Fifth Annual International Meeting of the Society for Cardiac Robotic Navigatio
Read more →STXSStereotaxis to Report Third Quarter 2021 Financial Results on November 11, 2021
ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 b
Read more →STXSStereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China
ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology i
Read more →STXS▼ -21.3%on this news
Stereotaxis Reports 2021 Second Quarter Financial Results
Reports 2021 Second Quarter Financial Results LOUIS, MO, Aug. 10, 2021 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June
Read more →STXSStereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. St. Louis
Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. Louis, July 26, 2021 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J.
Read more →STXSStereotaxis to Report Second Quarter 2021 Financial Results on August 10, 2021
ST. LOUIS, July 20, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 second quarter on Tuesday, August 10, 2021 bef
Read more →STXSStereotaxis Reports 2021 First Quarter Financial Results
Reports 2021 First Quarter Financial Results LOUIS, MO, May 10, 2021 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31
Read more →STXSStereotaxis to Report First Quarter 2021 Financial Results on May 10, 2021
ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before
Read more →STXSStereotaxis CEO Invited as Keynote Speaker at Robotic Surgery & Enabling Technologies Summit 2021
ST. LOUIS, April 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chairman and CEO, will serve as the keynote speaker at the Robotic Surgery & Enabli
Read more →STXSStereotaxis to Establish Global Headquarters in Downtown St. Louis Globe Building
ST. LOUIS, March 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it will move its global headquarters to the Globe Building in downtown St. Louis at the end of th
Read more →STXSStereotaxis Reports 2020 Full Year Financial Results St. Louis
Reports 2020 Full Year Financial Results Louis, Feb. 25, 2021 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended
Read more →STXSStereotaxis Announces Long-Term CEO Performance Stock Award St. Louis
Announces Long-Term CEO Performance Stock Award Louis, Feb. 24, 2021 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO performance stock award for David Fisch
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
ST. LOUIS, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 fourth quarter and full year ended December 31
Read more →STXSStereotaxis Reports 2020 Third Quarter Financial Results
Reports 2020 Third Quarter Financial Results LOUIS, MO, Nov. 9, 2020 - (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended Septem
Read more →STXSStereotaxis to Report Third Quarter 2020 Financial Results on November 9, 2020
ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 third quarter on Monday, November 9, 2020 befo
Read more →STXSStereotaxis CEO Invited to Speak on Plenary Panel at RAPS Convergence 2020
ST. LOUIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will serve as a panel speaker at the plenary session of RAP
Read more →STXSStereotaxis to Present at Three Investor Conferences in September
ST. LOUIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at three investor conferences in September 2020
Read more →STXSStereotaxis Reports 2020 Second Quarter Financial Results St. Louis, MO
Reports 2020 Second Quarter Financial Results Louis, MO, Aug. 6, 2020 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 3
Read more →STXSStereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support
ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote TeleRobotic Support. Dr. Gery Tomassoni of Baptist Health in Lexington, KY treated
Read more →STXSStereotaxis to Report Second Quarter 2020 Financial Results on August 6, 2020
ST. LOUIS, July 23, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 second quarter on Thursday, August 6, 2020 bef
Read more →STXSStereotaxis to be Added to the Russell 2000 and Russell 3000 Indexes
ST. LOUIS, June 22, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the
Read more →STXSStereotaxis to Present at Cowen 5th Annual FutureHealth Conference
ST. LOUIS, June 18, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at the Cowen 5th Annual FutureHealth Conference
Read more →STXSStereotaxis Robotic Technology Now Referenced In Over 400 Scientific Publications
Over 400 scientific publications now document clinical benefits of Stereotaxis robotic technology Most recent publication reviews outcomes of 1,003 consecutive robotic procedures at a single center ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the globa
Read more →STXSStereotaxis Announces $15 Million Common Stock Financing
Announces $15 Million Common Stock Financing LOUIS, May 26, 2020 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement
Read more →STXSSEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS This Separation Agreement and Release of All Claims (" Agreement ") is made between Stereotaxis, Inc., including its divisions, subsidiaries, parent and affiliated corporati
AGREEMENT AND RELEASE OF ALL CLAIMS Separation Agreement and Release of All Claims ("Agreement") is made between Stereotaxis, Inc., including its divisions, subsidiaries, parent and affiliated corporations, successors and assigns (individually and collectively, "Stereotaxis")
Read more →STXSStereotaxis Reports 2020 First Quarter Financial Results
Reports 2020 First Quarter Financial Results LOUIS, MO, May 5, 2020 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31,
Read more →STXSStereotaxis to Report First Quarter 2020 Financial Results on May 5, 2020
ST. LOUIS, April 30, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 first quarter on Tuesday, May 5, 2020 before
Read more →STXSStereotaxis Reports 2019 Full Year Financial Results
Reports 2019 Full Year Financial Results LOUIS, MO, March 10, 2020 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year e
Read more →STXSStereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic Navigation System
ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® Syst
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2019 Financial Results on March 10, 2020
ST. LOUIS, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 fourth quarter and full year ended December 31
Read more →STXSStereotaxis to Present at Three Investor Conferences in March
ST. LOUIS, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at three investor conferences in March 2020. C
Read more →STXSStereotaxis to Ring the Opening Bell of the New York Stock Exchange
ST. LOUIS, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange o
Read more →STXSStereotaxis CEO to Present at the 12th Annual LD Micro Main Event Investor Conference
ST. LOUIS, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th Annual LD Micro
Read more →STXSStereotaxis CEO to Present at the 12th Annual BIOMEDevice San Jose Conference
ST. LOUIS, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th annual BIOMEDevi
Read more →STXSStereotaxis Reports 2019 Third Quarter Financial Results
Reports 2019 Third Quarter Financial Results LOUIS, MO, Nov. 14, 2019 (GLOBE NEWSWIRE) - Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended Septemb
Read more →STXSStereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhythmias
ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’
Read more →STXSStereotaxis to Report Third Quarter 2019 Financial Results on November 14, 2019
ST. LOUIS, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE American: STXS) the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 third quarter ended September 30
Read more →STXSStereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias
ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Naviga
Read more →STXSStereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias
ST. LOUIS and BARCELONA, Spain, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’
Read more →STXSStereotaxis Announces CFO Transition
Announces CFO Transition LOUIS, MO, Sept. 16, 2019 - Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, ef
Read more →STXSStereotaxis Announces Uplisting to NYSE American
ST. LOUIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its common stock has been approved for listing on the NYSE American. The Company’s common s
Read more →STXSSTEREOTAXIS, INC. BALANCE SHEET UNAUDITED ACTUAL AND AS ADJUSTED JUNE 30, 2019
ACTUAL AND AS ADJUSTED June 30, 2019 as reported Adjustments as a result of August financing June 30, 2019 including August financing (Unaudited) (Unaudited) (Unaudited) Assets Current assets: Cash and cash equivalents $ 8,471,914 $ 23,13
Read more →STXSStereotaxis Reports 2019 Second Quarter Financial Results
Reports 2019 Second Quarter Financial Results LOUIS, MO, August 8, 2019 - Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a
Read more →STXSStereotaxis Announces $25 Million Private Placement
Announces $25 Million Private Placement LOUIS, MO, August 8, 2019 - Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select ins
Read more →STXSStereotaxis to Report Second Quarter 2019 Financial Results on August 8, 2019
ST. LOUIS, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 second quarter ended June 30, 2019 on T
Read more →STXSStereotaxis Announces the First Graduating Class of the Robotic Electrophysiology Fellows Program
ST. LOUIS, June 18, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the first graduating class from its Robotic Electrophysiology Fellows Program. The Robotic
Read more →STXSStereotaxis to Present at 9th Annual LD Micro Invitational
ST. LOUIS, May 29, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 9th
Read more →STXSStereotaxis and Osypka Enter Strategic Collaboration to Advance Robotic Catheter Technology
Development of next generation robotically-navigated magnetic ablation catheter fully owned by Stereotaxis Catheter designed to enhance patient care, improve therapy delivery, simplify catheter navigation, and strengthen commitment to open ecosystem Entered into additional busi
Read more →STXSStereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System
Innovative robotic surgery system, Stereotaxis Genesis™ RMN, enriches robotic magnetic navigation with increased efficiency, reduced size, and enhanced lab experience Genesis RMN System to be available in combination with Stereotaxis Imaging Model S, a next-generation x-ray syst
Read more →STXSStereotaxis Reports 2019 First Quarter Financial & Operational Results
Reports 2019 First Quarter Financial & Operational Results LOUIS, MO, May 9, 2019 - Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2
Read more →STXSStereotaxis to Showcase Innovation and Technology at Heart Rhythm 2019 and Report First Quarter 2019 Financial Results on May 8-9, 2019
Innovation Update Presentation on the Evening of May 8 at Heart Rhythm Society Innovation Update Press Releases and First Quarter Financial Release Issued Prior to the Market Open on May 9 First Quarter Investor Conference Call on May 9 at 9:00 a.m. Eastern Time ST. LOUIS, Apr
Read more →STXSStereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures
First patients successfully treated with robust integration of technologies Integrated technologies now commercially available ST. LOUIS and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS) and Acutus Medical today announced the first patients have
Read more →STXSStereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19
ST. LOUIS, March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress fro
Read more →STXSStereotaxis Reports 2018 Full Year Financial Results Record high annual recurring revenue of $27.8 million; 3% annual growth Positive annual net income for the first time in Company history despite significantly increase
Reports 2018 Full Year Financial Results Record high annual recurring revenue of $27.8 million; 3% annual growth Positive annual net income for the first time in Company history despite significantly increased R&D investments Innovation initiatives to be showcased in May a
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
ST. LOUIS, March 04, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 fourth quarter and full year ended Dec
Read more →STXSStereotaxis to Participate in BTIG Healthcare Investor Conference
ST. LOUIS, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to participate in th
Read more →STXSStereotaxis Announces Partnership with Kansas City Heart Rhythm Institute to Bring New Treatment to Arrhythmia Patients
ST. LOUIS, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias announced today a partnership with Kansas City Heart Rhythm Institute to bring new and cutting-edge treatments to
Read more →STXSStereotaxis to Present at the 11th Annual LD Micro Main Event Investor Conference
ST. LOUIS, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 11
Read more →STXSStereotaxis Reports 2018 Third Quarter Financial Results Continued progress on strategic innovation initiatives; expect to showcase in 1H 2019 4% recurring revenue growth; reaffirming 2018 record recurring revenue expect
Reports 2018 Third Quarter Financial Results Continued progress on strategic innovation initiatives; expect to showcase in 1H 2019 4% recurring revenue growth; reaffirming 2018 record recurring revenue expectations Conference call today at 10:00 a.m. Eastern Time LOUIS, M
Read more →STXSStereotaxis to Report Third Quarter 2018 Financial Results on November 12, 2018
ST. LOUIS, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018
Read more →STXSStereotaxis to Present at OTCQX Virtual Investor Conference for Domestic Companies
ST. LOUIS, Mo., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will present at the OTCQX Virtual Investor Conference for Domestic Companies.
Read more →STXSStereotaxis Reports 2018 Second Quarter Financial Results Progress on strategic internal innovation and external collaborations Continued growth in recurring revenue Positive cash flow from operations Reaffirming 2018 ex
Reports 2018 Second Quarter Financial Results Progress on strategic internal innovation and external collaborations Continued growth in recurring revenue Positive cash flow from operations Reaffirming 2018 expectations Conference call today at 10:00 a.m. Eastern Time
Read more →STXSStereotaxis to Report Second Quarter 2018 Financial Results on August 7, 2018
ST. LOUIS, July 31, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tu
Read more →STXSStereotaxis and Johnson & Johnson s Biosense Webster Extend Development Alliance and Supply Agreement
Stereotaxis and Johnson & Johnson s Biosense Webster Extend Development Alliance and Supply Agreement ST. LOUIS, MO, June 25, 2018 Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today th
Read more →STXSStereotaxis Announces Changes to its Board of Directors
Stereotaxis Announces Changes to its Board of Directors ST. LOUIS, MO, June 4, 2018 Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of d
Read more →STXSStereotaxis to Present at 8th Annual LD Micro Invitational
ST. LOUIS, May 22, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 8th
Read more →STXSStereotaxis Reports 2018 First Quarter Financial Results 3% year-over-year growth in recurring revenue Continued progress on strategic innovation initiatives; collaboration with Acutus Medical Increasing quantity and qua
Stereotaxis Reports 2018 First Quarter Financial Results ST. LOUIS, MO, May 14, 2018 Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended Marc
Read more →STXSStereotaxis to Report First Quarter 2018 Financial Results on May 14, 2018
ST. LOUIS, May 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Mon
Read more →STXSStereotaxis to Highlight Unique Advantages of Robotic Cardiac Ablation at Heart Rhythm 2018
ST. LOUIS, May 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at the
Read more →STXSStereotaxis and Acutus Medical Announce Strategic Collaboration
Formal testing supports joint use of the two systems Positive initial clinical experience demonstrates additive benefits of technologies Commitment to robust integration of technologies to enhance ease-of-use and lab efficiency ST. LOUIS and CARLSBAD, Calif., May 03, 2018 (GLO
Read more →STXSStereotaxis Announces Publication of Clinical Research Supplement Highlighting Robotic Navigation for Cardiac Arrhythmias
ST. LOUIS, May 01, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the Society for Cardiac Robotic Navigation (SCRN) has published a supplement in the Euro
Read more →STXSStereotaxis Announces Expanded European Labeling for Navigation in the Pericardial Space
ST. LOUIS, April 11, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that navigation in the pericardial space has been added to the CE Mark of the Niobe® magnet
Read more →STXSStereotaxis Announces $10.0 Million Non-Dilutive Financing from Early Warrant Exercise
Enables continued execution of innovation and commercial initiatives Non-dilutive to shareholders Long term lock-up agreement on exercised warrants Represents necessary first step on path to relist on NASDAQ ST. LOUIS, March 06, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTC
Read more →STXSStereotaxis Reports 2017 Fourth Quarter and Full Year Financial Results 7% year-over-year growth in fourth quarter global procedures and recurring revenue Substantial progress in delineating and initiating strategic inno
Stereotaxis Reports 2017 Fourth Quarter and Full Year Financial Results ST. LOUIS, MO, March 6, 2018 Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth qu
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018
ST. LOUIS, March 02, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 fourth quarter and full year ended Decemb
Read more →STXSStereotaxis Reports Preliminary Fourth Quarter 2017 Revenue Results Revenue of $7.6 million for the fourth quarter and $31.2 million for the full year 2017 Fourth quarter year-over-year revenue growth of 4% and procedure
Stereotaxis Reports Preliminary Fourth Quarter 2017 Revenue Results January 8, 2018 Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced preliminary revenue results for the fourth quarter o
Read more →STXSStereotaxis Receives Regulatory Approval of e-Contact™ Module in Canada
ST. LOUIS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has received regulatory clearance from Health Canada for its e-Contact™ Module, whic
Read more →STXSStereotaxis to Present at 29th Annual Piper Jaffray Healthcare Conference
ST. LOUIS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 29t
Read more →STXSStereotaxis Reports Third Quarter 2017 Financial Results 3% year-over-year growth in recurring revenue and 2% year-over-year growth in global procedures Reduced operating expenses leads to small quarterly operating profi
Stereotaxis Reports Third Quarter 2017 Financial Results ST. LOUIS, MO, November 9, 2017 Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended S
Read more →STXSStereotaxis to Report Third Quarter 2017 Financial Results on November 9, 2017
ST. LOUIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 third quarter ended September 30, 2017 on
Read more →STXSStereotaxis to Attend Asia Pacific Heart Rhythm Society Conference and Announces Japan Procedure Milestone
ST. LOUIS, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that physicians at Japanese hospitals have completed more than 500 ablation procedures using
Read more →STXSStereotaxis Reports Second Quarter 2017 Financial Results Stable recurring revenue and 2% year-over-year growth in global procedures Reduced operating expenses and operating loss Launch of e-Contact module in EU and prog
Stereotaxis Reports Second Quarter 2017 Financial Results ST. LOUIS, MO, August 10, 2017 Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended Ju
Read more →STXSStereotaxis to Report Second Quarter 2017 Financial Results on August 10, 2017
ST. LOUIS, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 second quarter ended June 30, 2017 on Thur
Read more →STXSStereotaxis Receives Second Odyssey Vision™ System Orders from Two Leading Heart Hospitals
ST. LOUIS, July 11, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has secured second Odyssey Vision™ system orders from McLaren Bay Region Hospital in M
Read more →STXSStereotaxis Launches the e-Contact™ Module in Europe
ST. LOUIS, June 15, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the European launch of the e-Contact™ module. The e-Contact module provides physicians with a
Read more →STXSStereotaxis Reports 2017 First Quarter Financial Results Procedures stable with gain in ventricular and decline in atrial procedures System sales at nadir; expect increase in latter half of 2017 from current initiatives
Stereotaxis Reports 2017 First Quarter Financial Results ST. LOUIS, MO, May 8, 2017 Stereotaxis, Inc. (OTCQX: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 3
Read more →STXSStereotaxis to Report First Quarter 2017 Financial Results on May 8, 2017
ST. LOUIS, April 27, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Mon
Read more →STXSStereotaxis’ Leadership in Robotic Cardiac Ablation to be Showcased at Heart Rhythm 2017 and First Annual Meeting of Society for Cardiac Robotic Navigation (Americas)
ST. LOUIS, April 25, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at McCo
Read more →STXSStereotaxis to Present at 29th Annual ROTH Conference
ST. LOUIS, March 07, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Acting Chief Executive Officer, is scheduled to present at t
Read more →STXSSTEREOTAXIS ANNOUNCES MANAGEMENT TRANSITION AND 2016 FINANCIAL RESULTS - Resignation of William C. Mills as CEO and Chairman - - Appointment of David Fischel as Acting CEO and Chairman - - Appointment of Nathan Fischel,
STEREOTAXIS ANNOUNCES MANAGEMENT TRANSITION AND 2016 FINANCIAL RESULTS - Resignation of William C. Mills as CEO and Chairman - - Appointment of David Fischel as Acting CEO and Chairman - - Appointment of Nathan Fischel, MD as Director - - Preliminary Unaudited Fourth Quarter
Read more →STXSStereotaxis Launches Interface between Niobe ES System and Philips’ State-of-the-art X-ray System
ST. LOUIS, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the release of an interface between its remote magnetic navigation system for electrophysiolog
Read more →STXSStereotaxis Reports 2016 Third Quarter Financial Results Completed $24 million private placement equity financing Retired all outstanding debt at significant discount Appointed three board members with extensive medical
Stereotaxis Reports 2016 Third Quarter Financial Results ST. LOUIS, MO, November 7, 2016 Stereotaxis, Inc. (OTCQX: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended Se
Read more →STXSStereotaxis to Report Third Quarter 2016 Financial Results on November 7, 2016
ST. LOUIS, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 third quarter ended September 30, 2016 on
Read more →STXSStereotaxis Technologies to be Highlighted at Society for Cardiac Robotic Navigation’s Inaugural Meeting in Amsterdam
ST. LOUIS, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its magnetic and robotic navigation systems will be represented at the inaugural meeting
Read more →STXSStereotaxis Awarded Patent in China for Vdrive System with V-Loop™ Manipulator
ST. LOUIS, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the State Intellectual Property Office of the People’s Republic of China has awarded a pa
Read more →STXSStereotaxis Completes Private Placement of $24 Million
Stereotaxis Completes Private Placement of $24 Million ST. LOUIS, MO, Sept. 29, 2016 Stereotaxis, Inc. (OTCQX: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has closed its previously announced private
Read more →STXSStereotaxis Announces Multiple Positive Strategic Updates - $24 Million Equity Investment - - Recruitment of Highly Experienced Board Members - - Retirement of Debt at Significant Discount
Stereotaxis Announces Multiple Positive Strategic Updates - $24 Million Equity Investment - - Recruitment of Highly Experienced Board Members - - Retirement of Debt at Significant Discount - ST. LOUIS, MO, Sept. 27, 2016 Stereotaxis, Inc. (OTCQX: STXS), a global leader in inn
Read more →STXSStereotaxis Reports 2016 Second Quarter Financial Results Ventricular tachycardia procedures increased 24% year over year, representing the 10th consecutive quarter of year-over-year volume growth Three Niobe system inst
Stereotaxis Reports 2016 Second Quarter Financial Results ST. LOUIS, MO, August 9, 2016 Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 20
Read more →STXSStereotaxis Completes Niobe System Installation at Kakogawa Hospital
ST. LOUIS, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the launch of its Niobe® remote magnetic navigation system at Kakogawa Central City Hospital, which be
Read more →STXSStereotaxis Common Stock to Begin Trading on OTCQX on
Stereotaxis Common Stock to Begin Trading on OTCQX on August 4, 2016 ST. LOUIS, MO, August 3, 2016 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that its shares of common stock will be elig
Read more →STXSStereotaxis to Report Second Quarter 2016 Financial Results on August 9, 2016
ST. LOUIS, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 second quarter ended June 30, 2016 on Tuesday, Au
Read more →STXSStereotaxis Releases Second Generation V-CAS Deflect™ System in Europe
ST. LOUIS, July 26, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the market release of its second generation V-CAS Deflect™ catheter advancement system in Europe. The
Read more →STXSStereotaxis Niobe ES System Installed at Texas Children’s Hospital
ST. LOUIS, July 08, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Texas Children’s Hospital in Houston has installed the Company’s Niobe® ES system, making it the
Read more →STXSStereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
ST. LOUIS, June 07, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe® ES magnetic navigation system and supporting
Read more →STXSStereotaxis Reports 2016 First Quarter Financial Results Ventricular tachycardia procedures increased 27% year over year, representing the third consecutive quarter of 20%+ quarterly volume growth Fourth Niobe system shi
Stereotaxis Reports 2016 First Quarter Financial Results ST. LOUIS, MO, May 9, 2016 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2016
Read more →STXSStereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
ST. LOUIS, May 04, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2
Read more →STXSStereotaxis to Report First Quarter 2016 Financial Results on May 9, 2016
ST. LOUIS, May 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 first quarter ended March 31, 2016 on Monday, May
Read more →STXSStereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive Robotic Navigation System
ST. LOUIS, April 29, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, “Operation of a R
Read more →STXSStereotaxis Completes Patient Enrollment for Niobe System’s Post-Market Surveillance in Japan
ST. LOUIS, March 30, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Takatsuki General Hospital, a leading acute care institution near Osaka, has reached the milest
Read more →STXSStereotaxis Reports 2015 Fourth Quarter and Full Year Financial Results New capital orders of $5.1 million in the fourth quarter, including two Niobe ES system orders in Japan Fourth quarter free cash flow of $1.6 millio
Stereotaxis Reports 2015 Fourth Quarter and Full Year Financial Results ST. LOUIS, MO, February 22, 2016 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarte
Read more →STXSStereotaxis to Participate at BTIG’s 2016 MedTech Conference
ST. LOUIS, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that William C. Mills, CEO, and Martin C. Stammer, CFO, will participate in BTIG’s 2016 MedTech Confe
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2015 Financial Results on February 22, 2016
ST. LOUIS, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2
Read more →STXSStereotaxis and Philips Extend Development Collaboration to Interface Latest Systems
ST. LOUIS and BEST, The Netherlands, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS) today announced Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Cooperation Agreement to facilitate development of a new interface bet
Read more →STXSStereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation Outcomes
ST. LOUIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it has initiated its first prospective, multi-center, randomized clinical study to compare radio
Read more →STXSStereotaxis Reports 2015 Third Quarter Financial Results -Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues- -Total Revenue for First Nine Months Increased 13% Year over Year t
Stereotaxis Reports 2015 Third Quarter Financial Results -Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues- -Total Revenue for First Nine Months Increased 13% Year over Year to $28.5 Million- -System Revenue for First Nine Months In
Read more →STXSStereotaxis to Report Third Quarter 2015 Financial Results on November 3, 2015
ST. LOUIS, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 third quarter ended September 30, 2015 on Tuesday
Read more →STXSStereotaxis Introduces Respiratory Compensation Feature for Remote Magnetic Navigation Procedures
ST. LOUIS, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company’s Niobe® remo
Read more →STXSStereotaxis Announces Results of Warrants Offering
Stereotaxis Announces Results of Warrants Offering ST. LOUIS, MO, October 8, 2015 Stereotaxis, Inc. ( Stereotaxis ) (NASDAQ: STXS) a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of its previously announced offeri
Read more →STXSStereotaxis Extends Warrants Offering Subscription Period Company CEO and CFO fully exercise subscription warrants
Stereotaxis Extends Warrants Offering Subscription Period Company CEO and CFO fully exercise subscription warrants ST. LOUIS, MO, Sept. 28, 2015 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announc
Read more →STXSStereotaxis Launches Vmotion Suite of Automation Features in U.S. Following FDA Clearance
ST. LOUIS, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first procedures performed in the U.S. with its Vmotion suite of automation features. Cleared by
Read more →STXSStereotaxis Announces Ex-Warrants Date of
Stereotaxis Announces Ex-Warrants Date of September 15, 2015 for Warrants Offering ST. LOUIS, MO, September 15, 2015 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that the NASDAQ Capital Ma
Read more →STXSStereotaxis Announces Ex-Warrants Date of September 15, 2015 for Warrants Offering
ST. LOUIS, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that the NASDAQ Capital Market has established September 15, 2015 as the "ex-warrants" date for its
Read more →STXSStereotaxis Announces Warrants Offering
ST. LOUIS, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will conduct a registered offering of subscription warrants to the holders of its common shar
Read more →STXSFORM OF INSTRUCTIONS AS TO USE OF STEREOTAXIS, INC. WARRANTS CERTIFICATES CONSULT THE WARRANTS AGENT, YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to a warrants offering (the Warrants Offerin
FORM OF INSTRUCTIONS WARRANTS CERTIFICATES CONSULT THE WARRANTS AGENT, YOUR BANK OR BROKER The following instructions relate to a warrants offering (the Warrants Offering ) by Stereotaxis, Inc., a Delaware corporation ( Stereotaxis ), to the holders of record (the Recordholde
Read more →STXSStereotaxis Awarded U.S. Patent Covering Transmission of Data for Odyssey(R) Solutions
ST. LOUIS, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,111,016 to the Company entitled "M
Read more →STXSStereotaxis Reports 2015 Second Quarter Financial Results - Total Revenue Increased 20% over Prior Year Second Quarter and 17% Year to Date - - Quarterly Operating Loss Decreased 25% Year over Year and 31% for the First
Stereotaxis Reports 2015 Second Quarter Financial Results - Total Revenue Increased 20% over Prior Year Second Quarter and 17% Year to Date - - Quarterly Operating Loss Decreased 25% Year over Year and 31% for the First Six Months Period - - First Niobe ES Procedures Performed
Read more →STXSStereotaxis to Report Second Quarter 2015 Financial Results on August 4, 2015
ST. LOUIS, July 28, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 second quarter ended June 30, 2015 on Tuesday, Au
Read more →STXSStereotaxis to Present at Cantor Fitzgerald Inaugural Healthcare Conference in New York on July 8, 2015
ST. LOUIS, July 2, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that William C. Mills, CEO, and Martin C. Stammer, CFO, will present at the Cantor Fitzgerald Inaugura
Read more →STXSStereotaxis to Present New Clinical Evidence and Product Innovations at Heart Rhythm 2015 in Boston
ST. LOUIS, May 13, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 36th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 14-16,
Read more →STXSStereotaxis Reports 2015 First Quarter Financial Results - Total Revenue Increased 14% over Prior Year First Quarter - - System Revenue Increased 112% Year over Year - - Operating Loss Decreased 37% Year over Year - - Si
Stereotaxis Reports 2015 First Quarter Financial Results - Total Revenue Increased 14% over Prior Year First Quarter - - System Revenue Increased 112% Year over Year - - Operating Loss Decreased 37% Year over Year - - Silicon Valley Bank Credit Facility Extended by Three Year
Read more →STXSStereotaxis Elects Medical Device Industry Veteran Duane DeSisto to Board of Directors
Stereotaxis Elects Medical Device Industry Veteran Duane DeSisto to Board of Directors May 4, 2015 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the election of medical device industry vete
Read more →STXSStereotaxis to Report First Quarter 2015 Financial Results on May 6, 2015
ST. LOUIS, April 29, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 first quarter ended March 31, 2015 on Wednesday
Read more →STXSStereotaxis Extends Silicon Valley Bank Credit Facility by Three Years
Stereotaxis Extends Silicon Valley Bank Credit Facility by Three Years ST. LOUIS, MO, Mar. 30, 2015 Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it has extended the maturity of its re
Read more →STXSStereotaxis Reports 2014 Fourth Quarter and Full Year Financial Results -Achieves First Quarterly Operating Income in Company History- -Increases Fourth Quarter Revenue 8% Year over Year and 10% Sequentially- -Reports Re
Stereotaxis Reports 2014 Fourth Quarter and Full Year Financial Results -Achieves First Quarterly Operating Income in Company History- -Increases Fourth Quarter Revenue 8% Year over Year and 10% Sequentially- -Reports Record Annual Recurring Revenue of $27.2 Million- -Reduces
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015
ST. LOUIS, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2014 fourth quarter and full year ended December 31, 2
Read more →STXSStereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures
ST. LOUIS, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) and Princess Grace Hospital of Monaco today announced the results of a recent clinical study conducted in Europe, which represent significant findings in terms of the Stereotaxis remote magnetic navigati
Read more →STXSStereotaxis Surpasses 75,000 Procedures With Remote Magnetic Navigation System
ST. LOUIS, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a leading provider of innovative technologies for the treatment of cardiac arrhythmias, announced today that more than 75,000 patient cases have been completed with its remote magnetic navigation technol
Read more →STXSStereotaxis Receives FDA Clearance of Vdrive(R) With V-CAS(TM) System Along With Regulatory Approval of Odyssey(R) System in Japan
ST. LOUIS, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) for its Vdrive with V-CAS Catheter Advancement System in the U.S., representing the Company's third Vdrive s
Read more →STXSStereotaxis Reports 2014 Third Quarter Financial Results -Improves System Revenue 89% Sequentially from Second Quarter 2014- -Completes Five New Niobe ES System Installations- -Secures First Niobe ES System Order in Japa
Stereotaxis Reports 2014 Third Quarter Financial Results -Improves System Revenue 89% Sequentially from Second Quarter 2014- -Completes Five New Niobe ES System Installations- -Secures First Niobe ES System Order in Japan- -Achieves Record Low Operating Expenses of $7.7 Milli
Read more →STXSFY 2014 Q3 Earnings Release Conference Call Transcript
FY 2014 Q3 Earnings Release Conference Call Transcript This transcript is provided by Stereotaxis, Inc. only for reference purposes. Information presented was current only as of the date of the conference call, and may have subsequently changed materially. Stereotaxis, Inc. doe
Read more →STXSStereotaxis to Report Third Quarter 2014 Financial Results on November 5, 2014
ST. LOUIS, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 third quarter ended September 30, 2014 on Wednesday, November 5, 2014 after the close of the U.S. financial markets. The Company will h
Read more →STXSStereotaxis Secures First Niobe(R) System Order in Japan
ST. LOUIS, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received the first commercial order for its Niobe ES magnetic navigation system in Japan from a leading hospital in Osaka. As part of its primary market strategy, the Company
Read more →STXSStereotaxis Receives FDA Clearance of Vdrive(TM) With V-Loop(TM) System
ST. LOUIS, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) to market its Vdrive Robotic Navigation System with V-Loop Variable Loop Catheter Manipulator in the U.S. T
Read more →STXSStereotaxis Reports 2014 Second Quarter Financial Results -Achieves Second Consecutive Quarter of Strong Recurring Revenue- -Improves Operating Loss by 16% from First Half of 2013- -Showcases Technologies at Preeminent I
Stereotaxis Reports 2014 Second Quarter Financial Results -Achieves Second Consecutive Quarter of Strong Recurring Revenue- -Improves Operating Loss by 16% from First Half of 2013- -Showcases Technologies at Preeminent Industry Events in Target Markets- -Launches Ablation His
Read more →STXSStereotaxis to Report Second Quarter 2014 Financial Results on August 4, 2014
ST. LOUIS, July 28, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the U.S. financial markets. The Company will host a con
Read more →STXSStereotaxis to Present Niobe(R) System Technology at Japan Heart Rhythm Society
ST. LOUIS, July 21, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will present at the 29th Annual Meeting of the Japanese Heart Rhythm Society in Tokyo beginning July 23, 2014. The three-day event is the first large-scale opportunity for the Com
Read more →STXSStereotaxis to Highlight Efficiency, Efficacy and Safety of Its Technology at Cardiostim 2014
ST. LOUIS, June 16, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will participate in Cardiostim 2014, the biennial scientific congress of the European Heart Rhythm Association (EHRA), to be held June 18-21, 2014 in Nice, France. The event repre
Read more →STXSStereotaxis Submits 510(k) Application to FDA for Vdrive(TM) With V-CAS(TM) Catheter Advancement System
ST. LOUIS, June 10, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has submitted a 510(k) Premarket Notification to the Food and Drug Administration (FDA) for the Company's Vdrive Robotic Navigation System with V-CAS Catheter Advancement System.
Read more →STXSStereotaxis to Present New Clinical Evidence, Features of Automated Technologies at Heart Rhythm 2014
ST. LOUIS, May 6, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced several firsts for its eleventh appearance at the annual Heart Rhythm Society (HRS) Scientific Sessions, to be held May 7-10, 2014 in San Francisco, CA. With a central theme of "Efficiency
Read more →STXSStereotaxis Reports 2014 First Quarter Financial Results -Records $7 Million in Recurring Revenue, Aided by Sequential Procedure Growth- -Furthers Marketing Strategy for Niobe System in Japan- -Expands Vdrive with V-Sono
Stereotaxis Reports 2014 First Quarter Financial Results -Records $7 Million in Recurring Revenue, Aided by Sequential Procedure Growth- -Furthers Marketing Strategy for Niobe System in Japan- -Expands Vdrive with V-Sono System Usage in U.S.; Receives Market Approval in Canad
Read more →STXSStereotaxis to Report First Quarter 2014 Financial Results on May 6, 2014
ST. LOUIS, April 30, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 first quarter ended March 31, 2014 on Tuesday, May 6, 2014 after the close of the U.S. financial markets. The Company will host a conf
Read more →STXSStereotaxis Submits 510(k) Application to FDA for Vdrive(TM) with V-Loop(TM) System
ST. LOUIS, April 1, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has submitted a 510(k) Premarket Notification with the Food and Drug Administration (FDA) for the Company's Vdrive Robotic Navigation System with V-Loop Variable Loop Catheter Man
Read more →STXSStereotaxis Expands Credit Facility With Silicon Valley Bank to $10 Million
ST. LOUIS, March 31, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into an amended credit agreement with Silicon Valley Bank (SVB) that replaces its existing $3 million revolving facility with a $10 million revolving facility schedul
Read more →STXSStereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results
-Announces Distribution Partnership in Japan- -Significantly Increases Working Capital by Year End- -Reduces Cash Burn for FY2013 to Record Low of $6.3 Million- -Achieves Lowest Reported Full Year Operating Loss of $8.8 Million- -Reconfirms Commitment to Technology Advancemen
Read more →STXSStereotaxis Signs Distribution Agreement for Niobe(R) Technology in Japan
ST. LOUIS, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into a definitive agreement with Medix Japan, Inc. and Hokushin Medical Co. Ltd. to distribute its Niobe Magnetic Navigation System for cardiac ablations in Japan. The
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014
ST. LOUIS, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2013 fourth quarter and full year ended December 31, 2013 on Tuesday, February 25, 2014 after the close of the U.S. financial markets. The C
Read more →STXSStereotaxis Appoints William C. Mills III to Chief Executive Officer
ST. LOUIS, Feb. 14, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that its board of directors has appointed Chairman William C. Mills III to Chief Executive Officer, effective February 12, 2014. Mr. Mills has been serving as interim CEO since April 2013
Read more →STXSStereotaxis Completes Clinical Trial of Vdrive(TM) With V-Loop(TM) System
ST. LOUIS, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has completed the clinical trial required for FDA clearance of the Company's Vdrive Robotic Navigation System with V-Loop Circular Catheter Manipulator. Results of the 120-patient
Read more →STXSStereotaxis to Present at Oppenheimer 24th Annual Healthcare Conference in New York on December 11, 2013
ST. LOUIS, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that William Mills, Chief Executive Officer, and Martin Stammer, Chief Financial Officer, will present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11th at 3
Read more →STXSStereotaxis Announces Results of Rights Offering
Stereotaxis Announces Results of Rights Offering ST. LOUIS, MO, November 27, 2013 Stereotaxis, Inc. ( Stereotaxis ) (NASDAQ: STXS) announced the results of its previously announced offering of subscription rights to purchase shares of its common stock, par value $0.001 per shar
Read more →STXSStereotaxis Rights Offering Expires November 21, 2013
ST. LOUIS, Nov. 20, 2013 (GLOBE NEWSWIRE) -- As a reminder to certain stockholders and warrant holders of Stereotaxis, Inc. (Nasdaq:STXS), as well as holders of separately purchased subscription rights, the current rights offering is scheduled to terminate this Thursday, November
Read more →STXSStereotaxis Reports Third Quarter 2013 Financial Results
-Increases System Revenue 34% Sequentially from Second Quarter 2013- -Improves Balance Sheet through Capital Transactions and Renewal of Silicon Valley Bank Credit Facility- -Receives Reimbursement Classification for Niobe in Japan- -Receives FDA Clearance of VdriveTM with V-S
Read more →STXSStereotaxis Announces Ex-Rights Date of November 4, 2013 for Rights Offering
ST. LOUIS, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Pursuant to its previously-announced rights offering, all stockholders and certain warrant holders of Stereotaxis, Inc. (Nasdaq:STXS) received subscription rights to purchase 1 share of common stock at a price of $3.00 per share for eve
Read more →STXSStereotaxis Announces Record Date for Rights Offering
Stereotaxis Announces Record Date for Rights Offering ST. LOUIS, MO, October 29, 2013 Stereotaxis, Inc. (NASDAQ: STXS) announced today that it has fixed 5:00 p.m. New York City time on October 31, 2013 as the record date for determination of stockholders (and eligible warrant h
Read more →STXSStereotaxis Niobe(R) System Receives Highest Reimbursement Classification in Japan
ST. LOUIS, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has classified its Niobe Magnetic Navigation System as a C2 medical device. The C2 classification recognizes the Niobe syste
Read more →STXSStereotaxis Announces Preliminary Third Quarter 2013 Financial Results in Preparation for Rights Offering
ST. LOUIS, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today released certain preliminary financial results for the 2013 third quarter in anticipation of its previously announced rights offering of common stock, which is expected to commence in the near futu
Read more →STXSStereotaxis Announces Renewal of Silicon Valley Bank Credit Facility
ST. LOUIS, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has completed the renewal of its revolving credit facility with Silicon Valley Bank (SVB). Under an amended credit agreement, Stereotaxis will extend its $3 million asset based r
Read more →STXSStereotaxis Announces Listing Transfer to NASDAQ Capital Market
ST. LOUIS, Aug. 16, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it received a positive determination from the NASDAQ Listing Qualifications Panel (the "Panel") on August 15, 2013 granting approval of the Company's request to transfer its listing
Read more →STXSStereotaxis Reports Second Quarter 2013 Financial Results; Announces Capital Transactions -Achieves 49% Sequential Improvement in System Revenue- -Secures Two Niobe ES Orders- -Narrows Operating Loss to $(1.8) Million- -
Stereotaxis Reports Second Quarter 2013 Financial Results; Announces Capital Transactions -Achieves 49% Sequential Improvement in System Revenue- -Secures Two Niobe ES Orders- -Narrows Operating Loss to -Obtains U.S. FDA Clearance of Vdrive with V-Sono System- -Receives Cas
Read more →STXSStereotaxis Receives FDA Clearance of Vdrive(TM) with V-Sono(TM) System
ST. LOUIS, July 29, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has been granted 510(k) clearance by the Food and Drug Administration (FDA) to market its Vdrive Robotic Navigation System with V-Sono Intracardiac Echocardiography (ICE) catheter
Read more →STXSStereotaxis Reports First Quarter 2013 Financial Results
-Year-over-Year Operating Loss Improves by 14%- -Open Positions in Sales Organization Impact Revenue Growth and New Orders- -Cash Burn is reduced to $1.1 M, a 73% YOY Improvement- -Operating Expenses Decrease 23% from Year Ago Period- -Niobe System Receives Japanese Regulator
Read more →STXSStereotaxis to Highlight Enhanced Technology and Results at HRS 2013 in Denver
ST. LOUIS, May 7, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced that it will highlight the milestones and clinical results achieved with its cutting-edge Epoch platform, as well as preview enhancements to the Epoch suite, at the 34th Annual Heart Rhythm Socie
Read more →STXSStereotaxis Changes Date of First Quarter 2013 Conference Call to May 13, 2013
ST. LOUIS, April 24, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced it has changed the date of its conference call to discuss its 2013 First Quarter financial results to Monday, May 13, 2013 after the close of the U.S. financial markets. The Company will
Read more →STXSStereotaxis to Report First Quarter 2013 Financial Results on May 2, 2013
ST. LOUIS, April 22, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2013 first quarter ended March 31, 2013 on Thursday, May 2, 2013 after the close of the U.S. financial markets. The Company will host a con
Read more →STXSStereotaxis Receives Regulatory Approval of Niobe(R) Technology in Japan; Begins Commercialization Efforts
ST. LOUIS, March 25, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received regulatory approval of its Niobe remote magnetic technology for cardiac ablations in Japan, a critical milestone in securing full market entry into the country. This
Read more →STXSStereotaxis CEO Michael Kaminski Steps Down; Board Chairman William Mills III to Serve as Interim CEO
ST. LOUIS, March 5, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that Michael Kaminski will step down as President and Chief Executive Officer, effective April 12, 2013, to accept a position as division president of a company in an unrelated field. The
Read more →STXSStereotaxis Reports 2012 Financial Results; Provides 2013 Outlook
-Achieves Record Fourth Quarter Cash Burn of Less than $0.1M- -Lowers Operating Loss to a Record $0.9M in Fourth Quarter, an 81% YOY Improvement- -Reduces Operating Expenses 31% in Quarter and for Full Year- -Grows Full Year Total Revenue 11%- -Hosts Conference Call Today at
Read more →STXSStereotaxis to Report Fourth Quarter and Full Year 2012 Financial Results on March 5, 2013
ST. LOUIS, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2012 fourth quarter and full year ended December 31, 2012 on Tuesday, March 5, 2013 after the close of the U.S. financial markets. The Compa
Read more →STXSStereotaxis CFO Steps Down to Pursue New Career Opportunity
ST. LOUIS, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) has announced that Sam Duggan, Chief Financial Officer, will resign from the Company, effective February 22, 2013. Serving as Stereotaxis CFO since October 2011, Mr. Duggan is leaving to accept a CFO posi
Read more →STXSStereotaxis to Present at Oppenheimer Healthcare Conference in New York on December 13, 2012
ST. LOUIS, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that Michael P. Kaminski, President and CEO, and Sam Duggan, CFO, will present at the Oppenheimer 23rd Annual Healthcare Conference on Thursday, December 13th at 2:45 p.m. ET. The conferen
Read more →STXSStereotaxis Reports 2012 Third Quarter Financial Results
-Achieves Revenue of $11.6 Million, up 35% over Prior Year Quarter- -Narrows Operating Loss to $0.9 Million, down 90% Year over Year- -Generates $7.1 Million in New Orders, including Four Niobe ES Orders, up 227% from Prior Year Quarter- -Conference Call Today at 4:30 p.m. Eas
Read more →STXSStereotaxis to Report Third Quarter 2012 Financial Results on November 5, 2012
ST. LOUIS, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for the third quarter 2012 on Monday, November 5, 2012 after the close of the U.S. financial markets. The Company will host a conference call and we
Read more →STXSStereotaxis Elects Euan S. Thomson, Ph.D., to Board of Directors
ST. LOUIS, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that Euan Thomson has been elected to its Board of Directors. The former President and CEO of Accuray Incorporated, Dr. Thomson, a medical physicist, has nearly 30 years experience in sci
Read more →STXSStereotaxis Experiencing Growth of Second System Orders
ST. LOUIS, Mo., Oct. 4, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that for the second consecutive quarter it has secured orders from hospitals looking to advance robotic research and support procedure growth through installation of a second Niobe ES
Read more →STXSStereotaxis Reports 2012 Second Quarter Financial Results
-- Generates Two Niobe ES Orders -- Exceeds Milestone With 41 Niobe ES Upgrades in First Half 2012 -- Reduces Operating Loss by 51% to $4.6 Million Over Prior Year Quarter -- Reports Diluted EPS of $0.32, Including Gain on Mark-to-Market Conversion Features; Adjusted Diluted
Read more →STXSStereotaxis Appoints Dr. Gery Tomassoni M.D. FHRS Chief Medical Officer
ST. LOUIS, Aug. 6, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that Gery Tomassoni M.D. FHRS has been appointed as Chief Medical Officer (CMO), effective immediately for a three-year term. Dr. Tomassoni is Director of Electrophysiology at Central Bapt
Read more →STXSStereotaxis to Report Second Quarter Financial Results on August 6, 2012
ST. LOUIS, July 26, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for the second quarter 2012 on Monday, August 6, 2012 after the close of the U.S. financial markets. The Company will host a conference call and web
Read more →STXSDan Johnston Chief Financial Officer 314-678-6007 Investor Contact: EVC Group, Inc. Doug Sherk & Gregory Gin 415-896-6820 Media Contact: Rick Green 314-678-6172 Stereotaxis and Biosense Webster Announce
Stereotaxis and Biosense Webster Announce New Strategic Collaboration Biosense Webster to Commercially Distribute Odyssey Solutions Worldwide ST. LOUIS, MO, May 5, 2011 Stereotaxis, Inc. (NASDAQ: STXS) announced today that it has entered into a new strategic collaboration with
Read more →STXSDan Johnston Chief Financial Officer 314-678-6007 Investor Contact: EVC Group, Inc. Douglas Sherk & Jenifer Kirtland 415-896-6820 Media Contact: EVC Group, Inc. Steve DiMattia 646-201-5445 Stereotaxis Re
Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook -2010 Revenue of $54.1 Million, Up 5.7% from 2009- -2010 Record Recurring Revenue of $22.9 Million, Up 24.0% from 2009- -2010 Global Capital Orders of $41.0 Million, Up 48% from 2009- -2010 Gross Mar
Read more →STXSDan Johnston Chief Financial Officer 314-678-6007 Investor Contact: EVC Group, Inc. Doug Sherk & Gregory Gin 415-896-6820 Media Contact: Rick Green Stereotaxis, Inc. 314-678-6172 Stereotaxis Announces El
Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors MO, February 22, 2011 Stereotaxis, Inc. (NASDAQ: STXS) today announced that Joseph D. Keegan, Ph.D., 55, was elected to its Board of Directors. Mr. Keegan is President and CEO of Fort BIO, Inc., a life scie
Read more →STXSDan Johnston Chief Financial Officer 314-678-6007 Investor Contact: EVC Group, Inc. Doug Sherk & Gregory Gin 415-896-6820 Media Contact: EVC Group, Inc. Steve DiMattia 646-201-5445 Stereotaxis Announces
Stereotaxis Announces Expansion of Catheter Strategic Partnership ST. LOUIS, MO, January 5, 2011 Stereotaxis, Inc. (NASDAQ: STXS) announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution o
Read more →STXSDan Johnston Chief Financial Officer 314-678-6007 Investor Contact: EVC Group, Inc. Doug Sherk & Gregory Gin 415-896-6820 Media Contact: EVC Group, Inc. Steve DiMattia 646-201-5445 Stereotaxis Receives C
Stereotaxis Receives Commitment to Increase and Extend Credit Facility $30 Million Revolving Credit Facility Commitment Extended to March 2012 and New $10 Million Term Loan Commitment Provided ST. LOUIS, MO, November 10, 2010 Stereotaxis, Inc. (NASDAQ: STXS) announced today th
Read more →STXSStereotaxis Inc. is Today's Focus Stock on MicroStockProfit.com
DALLAS, July 14, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Stereotaxis Inc. (Nasdaq:STXS). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment
Read more →Competitive Position
How STXS ranks across every disease it competes inCompetitive Position is a premium feature
See how STXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial